SYNCOM.NS
Syncom Healthcare Ltd
Price:
4.25
INR
Volume:
113,560
India | Pharmaceuticals
SYNCOM.NS EV/EBITDA
-306.8 %
Upside
As of 2025-07-12, the EV/EBITDA ratio of Syncom Healthcare Ltd (SYNCOM.NS) is -16.49. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SYNCOM.NS's latest enterprise value is 415 mil INR. SYNCOM.NS's TTM EBITDA according to its financial statements is -25 mil INR. Dividing these 2 quantities gives us the above SYNCOM.NS EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing EV/EBITDA multiples | 7.9x - 13.7x | 12.2x |
| Forward EV/EBITDA multiples | 6.8x - 9.4x | 8.2x |
| Fair Price | (7.94) - (8.67) | (8.79) |
| Upside | -286.8% - -304.0% | -306.8% |
4.25 INR
Stock Price
(8.79) INR
Fair Price
| (INR in millions except Fair Price) | |||
| Trailing | Forward | ||
| Market Cap (INR mil) | EV/EBITDA | EV/EBITDA | |
| Syncom Healthcare Ltd | 214 | N/A | N/A |
| Makers Laboratories Ltd | 909 | 4.7x | 3.9x |
| Veerhealth Care Ltd | 302 | 24x | 7.6x |
| Lactose India Ltd | 1,196 | 9.3x | 8.2x |
| Coral Laboratories Ltd | 2,777 | 5.7x | 5.4x |
| Auro Laboratories Ltd | 1,651 | 51.3x | 11.1x |
| Colinz Laboratories Ltd | 158 | 13.8x | 14.1x |
| Source Natural Foods and Herbal Supplements Ltd | 966 | 18.5x | 14.3x |
| Concord Drugs Ltd | 316 | 12.2x | 10.6x |
| Parenteral Drugs (India) Ltd | 86 | 3.1x | 3.1x |
| Industry median | 12.2x | 8.2x | |
| (*) EBITDA | -25 | -25 | |
| Enterprise value | (307) | (206) | |
| (-) Net debt | 201 | 201 | |
| Equity value | -508 | -407 | |
| (/) Outstanding shares | 50 | 50 | |
| Fair price | -10 | -8 | |